LIMINATUS PHARMA INC-CL A (LIMN) Stock Price & Overview
NASDAQ:LIMN • US53271X1081
Current stock price
The current stock price of LIMN is 0.1798 USD. Today LIMN is down by -0.11%. In the past month the price decreased by -23.75%.
LIMN Key Statistics
- Market Cap
- 8.069M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.56
- Dividend Yield
- N/A
LIMN Stock Performance
LIMN Stock Chart
LIMN Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to LIMN.
LIMN Earnings
LIMN Forecast & Estimates
LIMN Groups
Sector & Classification
LIMN Financial Highlights
Over the last trailing twelve months LIMN reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -38.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1990.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
LIMN Ownership
LIMN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 371.899B | ||
| AMGN | AMGEN INC | 15.37 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.1 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.62 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LIMN
Company Profile
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
Company Info
IPO: 2021-05-18
LIMINATUS PHARMA INC-CL A
6 Centerpointe Dr., #625
La Palma CALIFORNIA US
Employees: 0
Phone: 12132735453
LIMINATUS PHARMA INC-CL A / LIMN FAQ
What does LIMN do?
Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company is headquartered in La Palma, California. The company went IPO on 2021-05-18. The firm is engaged in the development of a second generation CD47 blockade antibody designed to prevent the induction of severe anemia and thrombocytopenia observed with first generation CD47 blockades. The Company’s candidate, IBA101, is a humanized anti-CD47 monoclonal antibody. The CD47 checkpoint inhibitor’s initial indication is expected to be patients with advanced solid cancers, including non-small cell lung cancer. IBA101 is a humanized anti-human CD47 monoclonal antibody with a human IgG4 Fc, designed to preferentially bind nucleated cells, such as immune and tumor cells, while sparing anucleate cells like red blood cells and platelets. IBA101 promotes macrophage-mediated phagocytosis of tumor cells.
What is the stock price of LIMINATUS PHARMA INC-CL A today?
The current stock price of LIMN is 0.1798 USD. The price decreased by -0.11% in the last trading session.
Does LIMINATUS PHARMA INC-CL A pay dividends?
LIMN does not pay a dividend.
How is the ChartMill rating for LIMINATUS PHARMA INC-CL A?
LIMN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
On which exchange is LIMN stock listed?
LIMN stock is listed on the Nasdaq exchange.
Should I buy LIMN stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LIMN.
When does LIMINATUS PHARMA INC-CL A (LIMN) report earnings?
LIMINATUS PHARMA INC-CL A (LIMN) will report earnings on 2026-06-01.